Drugs / Qianglidingxuan Tablets
Qianglidingxuan Tablets
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05521282 | Mar 2021 → Jun 2022 | essential hypertension | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Qianglidingxuan Tablets | “Based on the basic treatment, Qianglidingxuan Tablets were given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks.” NCT05521282 ↗ |
| Known as | QDT | “Qiangli Dingxuan tablet (QDT) is a formally approved Chinese patent medicine, which has been widely used as an adjunctive treatment for hypertension.” PMID 37492087 ↗ Jul 2023 |
| Known as | Qiangli Dingxuan tablet | “Qiangli Dingxuan tablet (QDT) is a formally approved Chinese patent medicine, which has been widely used as an adjunctive treatment for hypertension.” PMID 37492087 ↗ Jul 2023 |
| Known as | QLT | “Qianglidingxuan tablets(QLT) in the treatment of blood pressure in patients with mild to moderate essential hypertension.” NCT05521282 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “QDT is a formally approved Chinese patent medicine” PMID 37492087 ↗ Jul 2023 |